Top Markets
Coin of the day
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
株式のランク #29675
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
株価
$0.20877985
時価総額
$20.11M
変化(1日)
-3.03%
変化(1年)
-66.13%
JP
取引 Modalis Therapeutics Corporation (4883)

カテゴリー

Modalis Therapeutics Corporation(4883)の利益
2026 時点の利益 TTM: 0
Modalis Therapeutics Corporation の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Modalis Therapeutics Corporation の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
$-3.09B -
US
- -
CH